ArticleClinical Medicine Insights. Oncology2022

Local Therapy Combined With First-Line EGFR Tyrosine Kinase Inhibitor Achieves Favorable Survival in Patients With EGFR-Mutant Metastatic Non-Small Cell Lung Cancer.

Xiaotong Lu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.